BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 30098165)

  • 21. Frontline treatment for transplant-eligible multiple myeloma: A 6474 patients network meta-analysis.
    Sekine L; Ziegelmann PK; Manica D; da Fonte Pithan C; Sosnoski M; Morais VD; Falcetta FS; Ribeiro MR; Salazar AP; Ribeiro RA
    Hematol Oncol; 2019 Feb; 37(1):62-74. PubMed ID: 30129104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: A systematic review.
    Al-Ani F; Louzada M
    Eur J Haematol; 2017 Dec; 99(6):479-488. PubMed ID: 28885719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bortezomib in combination with thalidomide or lenalidomide or doxorubicin regimens for the treatment of multiple myeloma: a meta-analysis of 14 randomized controlled trials.
    Wang L; Xu YL; Zhang XQ
    Leuk Lymphoma; 2014 Jul; 55(7):1479-88. PubMed ID: 23998282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis.
    Giri S; Aryal MR; Yu H; Grimshaw A; Pathak R; Huntington SP; Dhakal B
    J Geriatr Oncol; 2020 Nov; 11(8):1285-1292. PubMed ID: 32513568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-refractory Multiple Myeloma.
    Mohyuddin GR; Hampton J; Aziz M; Khuder S; Malik S; McClune B; Abdallah AO
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):489-496. PubMed ID: 33962898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients.
    Djebbari F; Sharpley FA; McLain-Smith S; Vallance G; Eyre TA; Kothari J; Moore S; Ramasamy K
    PLoS One; 2020; 15(2):e0229469. PubMed ID: 32084254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
    Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
    J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany.
    Kuhr K; Wirth D; Srivastava K; Lehmacher W; Hellmich M
    Eur J Clin Pharmacol; 2016 Mar; 72(3):257-65. PubMed ID: 26671239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
    Syed YY
    Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group.
    Luoma S; Anttila P; Säily M; Lundan T; Heiskanen J; Siitonen T; Kakko S; Putkonen M; Ollikainen H; Terävä V; Sankelo M; Partanen A; Launonen K; Räsänen A; Sikiö A; Suominen M; Bazia P; Kananen K; Lievonen J; Selander T; Pelliniemi TT; Ilveskero S; Huotari V; Mäntymaa P; Tienhaara A; Jantunen E; Silvennoinen R
    Ann Hematol; 2019 Dec; 98(12):2781-2792. PubMed ID: 31673775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.
    Zheng Y; Shen H; Xu L; Feng J; Tang H; Zhang N; Chen X; Gao G
    J Immunol Res; 2018; 2018():7646913. PubMed ID: 30050957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bortezomib and lenalidomide as front-line therapy for multiple myeloma.
    Zou Y; Lin M; Sheng Z; Niu S
    Leuk Lymphoma; 2014 Sep; 55(9):2024-31. PubMed ID: 24067138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk adapted post-transplant maintenance in multiple myeloma.
    Vaxman I; Gertz M
    Expert Rev Hematol; 2019 Feb; 12(2):107-118. PubMed ID: 30696304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
    Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
    J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].
    Wang GM; Yang GZ; Huang ZX; Zhong YP; Jin FY; Liao AJ; Wang XM; Fu ZZ; Liu H; Li XL; Zhou JF; Zhang X; Hu Y; Meng FY; Huang XJ; Chen WM; Lu J
    Zhonghua Nei Ke Za Zhi; 2017 Jul; 56(7):500-506. PubMed ID: 28693058
    [No Abstract]   [Full Text] [Related]  

  • 37. Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review.
    Kumar A; Hozo I; Wheatley K; Djulbegovic B
    Am J Hematol; 2011 Jan; 86(1):18-24. PubMed ID: 21120867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
    Palumbo A; Hajek R; Delforge M; Kropff M; Petrucci MT; Catalano J; Gisslinger H; Wiktor-Jędrzejczak W; Zodelava M; Weisel K; Cascavilla N; Iosava G; Cavo M; Kloczko J; Bladé J; Beksac M; Spicka I; Plesner T; Radke J; Langer C; Ben Yehuda D; Corso A; Herbein L; Yu Z; Mei J; Jacques C; Dimopoulos MA;
    N Engl J Med; 2012 May; 366(19):1759-69. PubMed ID: 22571200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.
    Huang H; Zhou L; Peng L; Fu W; Zhang C; Hou J
    Leuk Res; 2014 Sep; 38(9):1048-54. PubMed ID: 25052306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation.
    Weisel K; Doyen C; Dimopoulos M; Yee A; Lahuerta JJ; Martin A; Travers K; Druyts E; Toor K; Abildgaard N; Lu J; Van Droogenbroeck J; Geraldes C; Petrini M; Voillat L; Voog E; Facon T
    Leuk Lymphoma; 2017 Jan; 58(1):153-161. PubMed ID: 27124703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.